Table 2. Percent of patients with early... | American Society of Hematology

Table 2.

Percent of patients with early mortality

	Early mortality, n/N (%)	P*
All HDTX patients	1187/3939 (30.1)	—
Year of first transplant		.002
<1997	238/654 (36.4)
1998-2003	299/997 (30.0)
2004-2008	362/1276 (28.4)
2009-2013	223/811 (27.5)
≥2014	65/201 (32.3)
Age, y		<.0001
<65	798/2892 (27.6)
≥65	389/1047 (37.2)
Sex		.92
Female	460/1522 (30.2)
Male	727/2417 (30.1)
Race/ethnicity		.30
White	1012/3407 (29.7)
African American	130/389 (33.4)
Other	45/143 (31.5)
GEP70		<.0001
Low risk	283/1620 (17.5)
High risk	216/352 (61.4)
Any chromosomal abnormality†		<.0001
No	550/2418 (22.8)
Yes	616/1478 (41.7)
TC6 classification†		<.0001
CCND1	83/390 (21.3)
CCND3	6/39 (15.4)
D1	106/565 (18.8)
D2	129/513 (25.2)
MAF/MAFB	63/134 (47.0)
MMSET	94/244 (38.5)
On a TT protocol		<.0001
No	810/2138 (37.9)
Yes	377/1801 (20.9)

	Early mortality, n/N (%)	P*
All HDTX patients	1187/3939 (30.1)	—
Year of first transplant		.002
<1997	238/654 (36.4)
1998-2003	299/997 (30.0)
2004-2008	362/1276 (28.4)
2009-2013	223/811 (27.5)
≥2014	65/201 (32.3)
Age, y		<.0001
<65	798/2892 (27.6)
≥65	389/1047 (37.2)
Sex		.92
Female	460/1522 (30.2)
Male	727/2417 (30.1)
Race/ethnicity		.30
White	1012/3407 (29.7)
African American	130/389 (33.4)
Other	45/143 (31.5)
GEP70		<.0001
Low risk	283/1620 (17.5)
High risk	216/352 (61.4)
Any chromosomal abnormality†		<.0001
No	550/2418 (22.8)
Yes	616/1478 (41.7)
TC6 classification†		<.0001
CCND1	83/390 (21.3)
CCND3	6/39 (15.4)
D1	106/565 (18.8)
D2	129/513 (25.2)
MAF/MAFB	63/134 (47.0)
MMSET	94/244 (38.5)
On a TT protocol		<.0001
No	810/2138 (37.9)
Yes	377/1801 (20.9)

Early mortality defined as death within 3 years of first ASCT, patients who were censored before 3 years of follow-up were excluded from the denominator because their true length of survival is unknown resulting from loss to follow-up.

χ²P value.

†

Excludes patients with missing data.

View Large

This Feature Is Available To Subscribers Only